Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Jérôme Hadjadj(Sorbonne Université), Benjamin Terrier(Hôpital Cochin), Luc Mouthon(Université Paris Cité), Paul Breillat(Inserm), R. Gauzit(Hôpital Cochin), Laura Barnabei(Inserm), Solen Kernéis(Hôpital Cochin), Tali‐Anne Szwebel(Hôpital Cochin), Darragh Duffy(Inserm), Alain Fischer(Inserm), Caroline Morbieu(Hôpital Cochin), Frédéric Pène(Centre National de la Recherche Scientifique), Sarah H. Merkling(Centre National de la Recherche Scientifique), Nader Yatim(Institut Pasteur), Flore Rozenberg(Centre National de la Recherche Scientifique), Camille Chenevier‐Gobeaux(Hôpital Cochin), Bruno Charbit(Institut Pasteur), Nicolas Carlier(Hôpital Cochin), Vincent Bondet(Inserm), Hélène Péré(Inserm), Nikaïa Smith(Institut Pasteur), Frédéric Rieux‐Laucat(Inserm), Pierre‐Louis Tharaux(Inserm), Aurélien Corneau(Sorbonne Université), Jean‐Marc Tréluyer(Hôpital Necker-Enfants Malades), Jérémy Boussier(Hôpital Avicenne), Catherine Blanc(Sorbonne Université), David Veyer(Inserm), Nathalie Marin(Hôpital Cochin), Nicolás Roche(Hôpital Cochin)
Cited by 3,166
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k